Thank you for the submission of your research manuscript to EMBO reports. We have now received the referee reports that are pasted below.
Neuro2A and differentiated primary hippocampal neurons. Particularly the latter has been very instrumental in identifying a role for both endocytic regulators in the polarized generation of Abeta. The most exciting part of their story is the fact that they discovered different sorting events that regulate the encountering of the substrate, APP, with the sheddase, BACE1. Bin1 seems to act mainly in axons where it regulates recycling of BACE1, while CD2AP may be a gatekeeper for endocytic sorting of APP in dendrites. KD of either proteins increases the residence time of APP and BACE1 in early/sorting endosomes, resulting in net accumulations of Abeta. Overall this is a very well documented manuscript with highly relevant data and findings; the authors use majorly imaging approaches and which are of high quality and well controlled. It provides significant progress in a still poorly explored area and a strong validation for the genetic studies. I include below some major and minor comments that need to be addressed to further improve the paper and make it suitable for publication.
Major comments:
The authors developed a semi-quantitative imaging approach for intracellular endogenous Abeta42 which provides an important read-out for studying the effects of altered expression of Bin1 and CD2AP. Although the 12F4 is often use to detect Abeta42, the endogenous levels in murine neurons remain extremely low for an easy detection by classical ICC and confocal microscopy. Given its weight for the paper, the authors should include more controls for their semi-quantitative immunofluorescence based Abeta42 assay, for instance using g-secretase and BACE1 inhibitors for an extended time: in both cases, specific Abeta42 immunofluorescencs should dramatically decrease underscoring the specificity of the assay. Secondly, the authors should rule out that some crossreactivity occurs with the C99 C-terminal fragment: an easy assay could be to transfect cells with C99-GFP in the absence or presence of a saturating doses of g-secretase inhibitor, or even better, in wt and PSEN dKO cells. The 12F4 should not give any signal in the latter cells or very low in the presence of inhibitors.
I wonder whether the immunoprecipitation data are really needed. Firstly, these are single experiments not independently confirmed by other methods and require more scrutiny. Secondly, without further identification of for instance interacting domains, these data remain suggestive. I don't see the importance of including them and at least it does not affect the paper by omitting them. The Discussion section is rather poor and requires improvement. The authors largely limit the discussion to re-iterating on their findings without much relation to the literature, next questions or future directions. For instance I miss some more in depth discussion on the extent that Bin1 and CD2AP are potential important risk factors. While there is no clear idea how expression levels are altered in LOAD, the current data suggest that it might be likely lower expression of Bin1 and CD2AP variants that contribute to disease. How is this studied for other candidate risk factors? Thirdly, the authors measure mostly intracellular Abeta when they evaluate the effects of altered expression of Bin1 and CD2AP. Interestingly, intracellular Abeta accumulation is an early feature in disease progression and in particular Abeta42 accumulates in MVBs where the more acidic environment promotes aggregation underscoring pathological relevance (reviewed in Peric and Annaert, 2015) . On the other hand endo/lysosomal abnormalities are also among the earliest features observed in AD pathogenesis. Also Cell reported just now a prominent role for PSEN2 in contributing most to this intracellular Abeta pool, which occurs, due to its restricted localization in MVBs/lysosomes (Sannerud et al., 2016, Cell) . Although speculative at the moment, it might be worth discussing whether LOAD risk factors may more pronouncedly affect the intracellular pool?
Minor (compulsory) comments:
Line 30: Excessive generation of Abeta is only a trigger in a subset of FAD. In many FAD mutations, like in PSENs, there is in fact less Abeta but the ratio shifts to longer Abeta.
Line 107 to 112: Reference to fig.2 is wrong and should be Fig. S2 (and appropriate panels), no? In this section, the authors suggest that the 40% loss after 60 min chase is in agreement with APP degradation in the lysosome. As supported by several papers, I do not dispute that APP is not degraded in this route, but I am less convinced that this occurs via classical lysosomal degradation. There are namely g-secretases in this route as well (see also Sannerud et al., 2016, but also earlier proteomic studies on isolated lysosomes (Pasternak et al)), and hence also this pool could follow the canonical degradation by dual processing. In fact, no real study exists that makes a balance sheet between the pool degraded through beta/alpha-gamma-secretase or lysosomal enzymes and the latter pool might be rather small. Line 163. Here an alternative explanation could be that CD2AP depletion results as well in halting cargo delivery from maturing endosomes in dendrites to mature lysosomes in cell bodies. This could explain the increase 22C11 in dendrites and decrease in cell bodies.
Line 225: '... recapitulating the early endosome enlargement that occurs early in AD.' This is too speculative here, and should be rather included in the discussion (see major comment).
Line 237: the authors state here that downregulation of Bin1 as well as CD2AP results in an increased colocalization of APP with BACE1. If so, why are opposite effects observed for APP-CTF ( Fig. 1h-i) ?
Line 254 and following: The authors measure here circularity and length of each carrer and conclude that they are increased in Bin1-depleted axons. However, I find this set of data a bit far-fetched given the low resolution of classic confocal microscopy. I would limit it here by stating that endosomes appear more extended and enlarged (so measure volume) as the actual evidence of a failure of tubule scission is far more convincing with the live imaging data (fig 6e-f) . Line 313: the authors didn't study KO of Bin1 and CD2AP but KD. So 'absence' is an overstatement.
Line 319: the link to cellular propagation of seeds is too speculative and lacks support.
Line 369: 'We uncover the mechanisms by which APP and BACE1 segregate at early endosomes..." Although the authors have revealed novel sorting regulation, they ignore other mechanisms that also regulate the encounter/segregation of APP and BACE1. For instance Sannerud et al (2011) demonstrated that APP and BACE1 follow distinct internalization routes in cells and neurons which should be included in the discussion. Moreover, worth mentioning is the fact that the contribution of axonally produced Abeta is very low compared to dendritic Abeta: this is relevance in a discussion on the relative contributions of Abeta pools to the disease or to propagation.
Specific remarks on the figures:
-For both Bin1 and CD2AP independent siRNA should be tested on a few basic readouts to be sure that the effects are not caused by off-targets. - Fig. 1I shows a decrease in APP-CTF/APP while there is no effect on this ratio in FigS1d. Please explain.
-It gives a better overview if panels S4d-e are included in Figure 3 (connected to panel I).
-I find the presentation of the data in figures S2 and S3 confusing. A better way might be to cluster the data on APP in S2 and on BACE1 in S3. -Fig S4b: immunostaining for Bin1/Ank is not convincing. It should demonstrate Bin1 in axons but most is in dendrites (inset).
Referee #2:
In this study, Ubelmann et al explore the role of Bin1 and CD2AP, two genes implicated as risk factors for late-onset Alzheimer's disease (AD). Both are regulators of endocytic trafficking, but their role in development of AD is yet unknown. The authors argue that both Bin1 and CD2AP depletion increase production of amyloid beta by increasing the interaction between APP and BACE1, though they act differently in the dendritic and axonal compartments. The authors report that Bin1 depletion prevents BACE1 recycling back to the plasma membrane in the axon, whereas CD2AP depletion prevents APP lysosomal degradation in the dendrite. The route of APP through the endo-lysosomal pathway and its points of regulation are of significant interest to the field of AD, both to understand how AD pathology develops and to identify potential targets for AD therapeutics.
Overall, the paper is well laid out and the experiments are clear. The authors extensively studied the differential regulation of APP processing in axons versus dendrites and provided mechanistic clues as to the potential role of Bin1 and CD2AP in AD pathology. However, there are a few elements which need to be addressed before publication and are as follows:
Major critiques:
1. In light of a recent manuscript that have come out regarding Bin1 and its role in BACE1 trafficking (Miyagawa et. al., 2016) , the authors should discuss how their data supports or refutes these new findings.
2. The authors interpret that the residual 22C11 signal seen in many of their siCD2AP experiments (for example, Figure 2d ) is due to a lack of APP lysosomal degradation because APP is not sorted into intraluminal vesicles (ILVs). However, lysosomal degradation is not specifically tested by any kind of inhibitor (bafilomycin, NH4Cl) and in fact the retention of 22C11 signal could be due to an inhibition of cleavage of the N-terminal APP due to APP sequestration in ILVs. The authors should specifically test lysosomal degradation using both immunofluorescence and biochemical techniques or adjust their interpretation accordingly.
Other critiques:
3. In figure 1 , it is important to show the specificity of AB42 staining, perhaps by conducting experiments in an APP knockdown background or with BACE1 or gamma-secretase inhibitors.
4. In figure 1 , what happens to intracellular levels of AB40? Since there are changes in extracellular secreted AB40, intracellular levels should be examined as well. Additionally, the authors state that there is a tendency for higher secretion of AB42, which is not clear in figure (1g) . How do they explain a decrease in extracellular AB40?
5. In figure 1 and S1, the method of normalization of APP-CTF levels is inconsistent, either to fulllength APP (Fig. 1h) or tubulin (Fig. S1d) . The authors should be consistent.
6. In figure 2 , the authors should include label of 22C11 antibody staining, and include time of chase for each experiment 7. In figure 3d, should the y-axis label be % of time point 0?
8. In figures 6 & 7, the quantifications lack error bars. Even if they are % values from pooled experiments, the authors should express the variability from independent experiments. Data should be quantified such that the amount of variability between experiments can be expressed. Alternatively, they can use more appropriate statistical tests, such as chi-square.
Referee #3:
In this manuscript, authors examined the role of Bin1 and CD2AP in Abeta production and vesicular trafficking in neurons. They found that downregulation of Bin1 and CD2AP increased the production of Abeta by distinct mechanisms. Bin1 regulates BACE1 recycling from early endosome, and CD2AP controls the sorting of APP to the degradation pathway. Depletion of CD2AP and Bin1 increased the encounter of APP and BACE1 at early endosome, thereby increasing the Abeta production. The research design is adequate, the methods used for this study and data obtained are solid. I have several comments and suggestions for the authors to consider improving the quality of the paper: 1) They have shown that knockdown of CD2AP and Bin1 altered the levels of APP-CTFs (Fig. 1h) . As gamma-secretase is also involved in the regulation of APP-CTF metabolism, the authors should show the levels of the gamma-secretase (e.g., nicastrin) in the lysates of siRNA-treated cells to exclude the possibility that the gamma-secretase activity was controlled.
2) It is general concern that tagging to intracellular region of the cargos affects their vesicular trafficking. Authors should examine the subcellular localization of endogenous APP as well as BACE1 in Bin1 or CD2AP-depleted N2a cells (or primary neurons) by immunocytochemistry.
3) Authors indicated that knockdown of CD2AP inhibited the sorting of APP to the ILVs. However, the levels of APP holoprotein was now altered in siCD2AP treated cells. Why? Authors should discuss this issue. We would like to thank you for the opportunity to revise our EMBOR-2016-42738V1 manuscript entitled "Bin1 and CD2AP polarise the endocytic generation of beta-amyloid" based on the positive initial reviews. We believe that our work is a very important contribution to the understanding of the cell biological mechanisms of late-onset Alzheimer's disease (AD). We would also like to thank the three reviewers for their constructive comments, which helped us to significantly improve the manuscript. We have addressed all points raised by the reviewers.
Importantly, regarding reviewer 1 and 2 concerns with the sensitivity and specificity of the antibodies used in our novel method to detect endogenous Aβ42 we have added a whole new figure (EV1) that includes all control experiments suggested. Moreover, we included, for review only, data from Pr. Gunnar K. Gouras (Lund University) using APP knockout neurons.
Regarding reviewer's 1 suggestion of removing the co-IP data from the paper (point 2), we would like to ask your opinion. We agree with the reviewer that co-IP does not prove interaction. Thus we altered our interpretation of the data to indicative of association but would prefer to keep the data in the paper since it strengthens our findings.
Regarding reviewer's 1 and 3 suggestions we expand our discussion with two new subsections and discussed the recent findings by Miyagawa et. al 2016.
Regarding reviewer's 1 and 2 concerns about APP degradation in the lysosome we have performed the suggested experiments of APP degradation in the presence of lysosomal inhibitor ( Fig. EV3C  and EV3D ). We address each point brought up by the three reviewers below and highlighted in the text all changes in yellow.
Referee #1
Major comments:
The authors developed a semi-quantitative imaging approach for intracellular endogenous Abeta42 which provides an important read-out for studying the effects of altered expression of Bin1 and CD2AP. Although the 12F4 is often use to detect Abeta42, the endogenous levels in murine neurons remain extremely low for an easy detection by classical ICC and confocal microscopy.
Given its weight for the paper, the authors should include more controls for their semi-quantitative immunofluorescence based Abeta42 assay, for instance using g-secretase and BACE1 inhibitors for an extended time: in both cases, specific Abeta42 immunofluorescencs should dramatically decrease underscoring the specificity of the assay. The Discussion section is rather poor and requires improvement. The authors largely limit the discussion to re-iterating on their findings without much relation to the literature, next questions or future directions. For instance I miss some more in depth discussion on the extent that Bin1 and CD2AP are potential important risk factors. While there is no clear idea how expression levels are altered in LOAD, the current data suggest that it might be likely lower expression of Bin1 and CD2AP variants that contribute to disease. How is this studies for other candidate risk factors? Secondly, the authors measure mostly intracellular Abeta when they evaluate the effects of altered expression of Bin1 and CD2AP. Interestingly, intracellular Abeta accumulation is an early feature in disease progression and in particular Abeta42 accumulates in MVBs where the more acidic environment promotes aggregation underscoring pathological relevance (reviewed in Peric and Annaert, 2015). On the otherhand endo/lysosomal abnormalities are also among the earliest features observed in AD pathogenesis. Also Cell reported just now a prominent role for PSEN2 in contributing most to this intracellular Abeta pool, which occurs, due to its restricted localization in MVBs/lysosomes (Sannerud et al., 2016, Cell). Although speculative at the moment, it might be worth discussing whether LOAD risk factors may more pronouncedly affect the intracellular pool?
Response Fig. S2 (and appropriate panels), no? In this section the authors suggest that the 40% loss after 60 min chase is in agreement with APP degradation in the lysosome. As supported by several papers, I do not dispute that APP is not degraded in this route, but I am less convinced that this occurs via classical lysosomal degradation.
There are namely g-secretases in this route as well (see also Sannerud et al., 2016, but also earlier proteomic studies on isolated lysosomes (Pasternak et al)), and hence also this pool could follow the canonical degradation by dual processing. In fact, no real study exists that makes a balance sheet between the pool degraded through beta/alpha-gamma-secretase or lysosomal enzymes and the latter pool might be rather small. Line 163. Here an alternative explanation could be that CD2AP depletion results as well in halting cargo delivery from maturing endosomes in dendrites to mature lysosomes in cell bodies. This could explain the increase 22C11 in dendrites and decrease in cell bodies.
Response: This is a very interesting point that reviewer #1 raises that we have now included in lines 181-183.
Response: We have moved this to the discussion (line 421).
Line 237: the authors state here that downregulation of Bin1 as well as CD2AP results in an increased colocalization of APP with BACE1. If so, why are opposite effects observed for APP-CTF ( Fig. 1h-i Line 254 and following: The authors measure here circularity and length of each carrer and conclude that they are increased in Bin1-depleted axons. However, I find this set of data a bit far-fetched given the low resolution of classic confocal microscopy. I would limit it here by stating that endosomes appear more extended and enlarged (so measure volume) as the actual evidence of a failure of tubule scission is far more convincing with the live imaging data (fig 6e-f 
Response: We have now added the indicated references in line 304. To clarify that APP-RFP identifies both APP full length and APP -CTFs we have extended the description of this construct (lines 249 and 325).
Line 313: the authors didn't study KO of Bin1 and CD2AP but KD. So 'absence' is an overstatement.
Response: We have deleted "absence" (line 337) and throughout the manuscript.
Response: We have removed the link to cellular propagation of amyloid seeds.
Line 369: 'We uncover the mechanisms by which APP and BACE1 segregate at early endosomes..." Although the authors have revealed novel sorting regulation, they ignore other mechanisms that also regulate the encounter/segregation of APP and BACE1. For instance, Sannerud et al (2011) demonstrated that APP and BACE1 follow distinct internalization routes in cells and neurons, which should be included in the discussion. Moreover, worth mentioning is the fact that the contribution of axonally produced Abeta is very low compared to dendritic Abeta: this is relevance in a discussion on the relative contributions of Abeta pools to the disease or to propagation. It gives a better overview if panels S4d-e are included in Figure 3 (connected to panel I).
Response: We have now included the panel S4d in figure 3 as panel 3I and panel S4E in figure 4 as panel 4J.
I find the presentation of the data in figures S2 and S3 confusing. A better way might be to cluster the data on APP in S2 and on BACE1 in S3. Fig 3I, 3J and 3K of the revised version).
Referee #2:
Overall, the paper is well laid out and the experiments are clear. The authors extensively studied the differential regulation of APP processing in axons versus dendrites and provided mechanistic clues as to the potential role of Bin1 and CD2AP in AD pathology. However, there are a few elements which need to be addressed before publication and are as follows: 
Miyagawa et al. concluded that there was a defect in BACE1 degradation, based on increased BACE1 total levels and decreased colocalization with LAMP1 (by fractionation). A shortcoming of their study is however that pulse-chase analysis of BACE1 degradation that would more rigorously analyse BACE1 degradation was not performed. Moreover, BACE1 recycling was not examined. We performed rigorous pulse-chase analysis of BACE1 recycling and degradation in n2a cells and primary neurons as well as analysis of BACE1 total levels. We observed a defect in BACE1 recycling in both cell types (Fig. 2I-L, 4C and 4D). However, pulse-chase analysis of BACE1 revealed no difference (Fig. EV4C) neither western blot analysis of BACE1 total levels (Fig. EV6C). Together our data are not consistent with a defect in BACE1 degradation. This could be due to differences in methodology and in the time of Bin1 depletion. Miyagawa et al. performed 6 days of complete Bin1 deletion while we did knockdown for 72h of transient siRNA transfection. Maybe the extra 3 days of Bin1 depletion are necessary for a defective BACE1 recycling to affect BACE1 total levels. Miyagawa et al. do not describe a mechanism for how Bin1 controls BACE1 degradation while we provide direct evidence for Bin1 to function in the scission of BACE1 tubules necessary for efficient recycling from early endosomes. We have now mentioned and discussed Miyagawa et al. results in lines 116 of the results and 379 of the discussion.
The authors interpret that the residual 22C11 signal seen in many of their siCD2AP experiments (for example, Figure 2d ) is due to a lack of APP lysosomal degradation because APP is not sorted into intraluminal vesicles (ILVs). However, lysosomal degradation is not specifically tested by any kind of inhibitor (bafilomycin, NH4Cl) and in fact the retention of 22C11 signal could be due to an inhibition of cleavage of the N-terminal APP due to APP sequestration in ILVs. The authors should specifically test lysosomal degradation using both immunofluorescence ane biochemical techniques or adjust their interpretation accordingly.
Response: We thank reviewer 2 and reviewer 1 for raising this point. We have now specifically tested and found APP lysosomal degradation inhibited upon leupeptin treatment using both immunofluorescence and biochemical techniques (Fig. EV3C and EV3D). Please also see minor comments point 2 from reviewer 1. We would also like to point out that 22C11 retention was observed after leupeptin treatment similarly to treatment with siCD2AP, supporting that the residual 22C11 observed likely results from delayed lysosomal degradation. Moreover, please note that upon CD2AP depletion APP/APP CTFs was observed retained at the endosomal limiting membrane and not sequestered in ILVs (Fig. 7).
In figure 1 , it is important to show the specificity of AB42 staining, perhaps by conducting experiments in an APP knockdown background or with BACE1 or gamma-secretase inhibitors. (Courtesy of Isak Martinsson and Gunnar K. Gouras, Lund University)
We performed Aβ42 immunofluorescence with both antibodies in the presence of prolonged treatment (48h) with DAPT (suggested by reviewer 1), and, as suggested by reviewers 1 and 2, with BACE inhibitor (Fig EV1B). Following the advice of reviewer 1 we also performed immunostainings on cells overexpressing the beta-cleaved APP-CTF (C99) in presence or absence of DAPT to rule out any cross-reactivity of the antibodies with APP cleavage byproducts (Fig. EV1C and EV1D
In figure 1 , what happens to intracellular levels of AB40? Since there are changes in extracellular secreted AB40, intracellular levels should be examined as well.
Response: Following this excellent suggestion by reviewer 2 we measured intracellular Aβ40 in N2a cells depleted for Bin1 or CD2AP by immunofluorescence using an antibody specific for Aβ40 (Fig EV2D). Aβ40 increased intracellularly upon Bin1 knockdown and remained unchanged upon CD2AP knockdown (line 96).
Additionally, the authors state that there is a tendency for higher secretion of AB42, which is not clear in figure (1g) . How do they explain a decrease in extracellular AB40?
Response: We agree that a tendency for higher secretion of Aβ42 is not clear in Fig. 1G 
CD2AP depletion by potentially inhibiting ILVs formation at MVBs would impair APP degradation, inhibit exosome formation and thus secretion of Aβ40-associated with exosomes. We have now discussed this (lines 374 and 403).
In figure 1 and S1, the method of normalization of APP-CTF levels is inconsistent, either to fulllength APP (Fig. 1h) or tubulin (Fig. S1d) . The authors should be consistent. Fig. EV1D to full length APP as in Fig. 1H to keep the results consistent as pointed out by reviewer 2.
Response: We have now changed the method of normalization in
In figure 2 , the authors should include label of 22C11 antibody staining, and include time of chase for each experiment
Response: We have included the label 22C11 and M1, the anti-Flag-BACE1 antibody used and the respective times of pulse and chase for each experiment.
In figure 3d , should the y-axis label be % of time point 0?
Response: We recognize reviewer 2's point. Ideally we would normalize it to time zero as we did when we measured the total amount of endocytosis per N2a cells (Fig. 2E) or by biotinylation of primary neurons (Fig. 3F) Response: Fig. 6B, 7D and 7I now show the variability of the independent experiments analyzed.
Referee #3:
In this manuscript, authors examined the role of Bin1 and CD2AP in Abeta production and vesicular trafficking in neurons. They found that downregulation of Bin1 and CD2AP increased the production of Abeta by distinct mechanisms. Bin1 regulates BACE1 recycling from early endosome, and CD2AP controls the sorting of APP to the degradation pathway. Depletion of CD2AP and Bin1 increased the encounter of APP and BACE1 at early endosome, thereby increasing the Abeta production. The research design is adequate, the methods used for this study and data obtained are solid. I have several comments and suggestions for the authors to consider improving the quality of the paper: 1) They have shown that knockdown of CD2AP and Bin1 altered the levels of APP-CTFs (Fig. 1h) .
As gamma-secretase is also involved in the regulation of APP-CTF metabolism, the authors should show the levels of the gamma-secretase (e.g., nicastrin) in the lysates of siRNA-treated cells to exclude the possibility that the gamma-secretase activity was controlled.
Response: We thank the reviewer for raising this point. We have analyzed the levels of nicastrin as suggested in the lysates of siRNA-treated cells and found no significant alterations in the levels of nicastrin upon siRNA treatment (See Fig. EV2F), suggesting that gamma-secretase is unaltered upon Bin1 or CD2AP siRNA treatment (line 107).
2) It is general concern that tagging to intracellular region of the cargos affects their vesicular trafficking. Authors should examine the subcellular localization of endogenous APP as well as BACE1 in Bin1 or CD2AP-depleted N2a cells (or primary neurons) by immunocytochemistry. (Fig. 1H, 1I, EV2E) ; endogenous APP degradation upon plasma membrane biotinylation ( Fig. 3E and 3F) ; endogenous co-ip with CD2AP (Fig. 3G) ; and importantly, we analyzed the subcellular localization of endogenous APP to early endosomes of CD2AP-depleted primary neurons by immunofluorescence and spinning-disk confocal microscopy ( Fig. 7A and 7B ) and dSTORM super-resolution microscopy (Fig. 7H, 7I and 7J) . These results were consistent with the ones obtained using exogenous expression of APP, indicating that tagging does not significantly affect APP vesicular trafficking. Regarding endogenous BACE1, we analyzed endogenous BACE1 total levels by western blot (Fig. S6C) ; and detected an endogenous co-ip with Bin1 (Fig. 4E) We have finally received all referee comments on your revised manuscript that are included below.
Response: Reviewer 3's concern with the study of exogenous proteins is a valid point, that we have tried to address by analyzing endogenous proteins whenever possible. Concerning APP, we analysed endogenous APP processing
While referees 2 and 3 did not raise concerns, referee 1 is still not convinced by the antibodies used and the coIP data. Upon cross-commenting, referee 3 agrees with referee 1 and suggests experiments to address the concerns. These comments are also pasted below. We usually only allow one round of revision. However, in this case, all referees indicate in the manuscript summary table that the findings are novel and interesting, and we would like to publish your study if the remaining concerns can be satisfactorily addressed. I would therefore like to give you the opportunity to do so, if you think this can be done in a reasonable timeframe.
It is our journal policy that manuscripts should be accepted at the latest 6 months after a first decision was made, which was in June in your case. We should therefore accept your manuscript before the end of December. Please let me know whether you think that the outstanding concerns can be addressed in the next few weeks/months.
Please note that we can only offer a maximum of 5 EV figures at the moment. Additional extra figures will need to be included in an Appendix file. Please see our guide to authors for more information. Please also add a scale bar to figure EV1c.
REFEREE REPORTS
Referee #1:
The authors have submitted a revised manuscript where they have addressed the critiques of the reviewers. Major concerns were related to the specificity of the antibodies used to detect Abeta42 by imaging, the co-IP data, additional controls to distinguish lysosomal degradation and the confrontation with Miyagawa et al (2016) . The new version is indeed improved and the authors have satisfactorily many of the raised issues by including new controls and performing some additional experiments. There are however some remaining issues related to my major critiques that needs some more scrutiny.
With respect to the specificity of the Abeta42 antibodies, the first answer is not to the point: it is not because there are 246 papers using these antibodies that paper 247 is OK. The authors make the wrong conclusion that what is published is per definition correct: how many of these 246 papers provided proper controls for antibody specificity? There are a zillion antibodies actively used in the AD field directed against any risk factor or APP fragment. I can assure the authors that a dramatic high number of antibodies to for instance g-secretase subunits, APP, ADAM10 basically fail when checked in the respective KO backgrounds. Nevertheless, there are even more papers published using such antibodies. With respect to the two anti-Abeta42 antibodies, the authors support their claim for specificity by using g-secretase and bace1 inhibitors and providing data (via their collaborator) in APP KO neurons. The authors have to admit that the latter are not 100% conclusive or supportive. I can maybe live with the specificity of the 12F4 antibody as the APP KO shows little background. But the H31L21 shows on the contrary still (very) high backgrounds particularly in the cell body but as well in the dendrites: It is for me very difficult to distinguish major differences between the staining in the wt vs APP KO dendrites. In a way this is reflected in the quantifications using DAPT (but also Compount IV) where 24 to 48hrs inhibition only gives a moderate drop (30% to 50% for H31L21 and even less (25% to35%) for 12F4) in Abeta42: in such a time span these inhibitors should give drops up to 80%. So, to my opinion this is largely caused by the inherent high backgrounds these antibodies generate in ICC applications (similar analysis by ELISA on N2A would prove/disprove my case). The authors didn't make a stronger case by providing the APP KO and DAPT data. However, I cannot deduce from the data and figures which experiments were done with the 12F4 or H31L21 antibody.
With respect to the co-IP data, the authors maintain them in the manuscript with only a minor change on interpretation (from 'interaction' to 'suggestive for interaction'). Again, the authors make the wrong argumentation that this might boost interest in the search for interaction domains. My point was that if co-IP data are not scrutinized with the proper controls, they are not reliable: it doesn't make any sense to use them to steer the community into further interaction studies. The only control in these experiments is the inclusion of control IgG. That is not sufficient to claim (suggestive) interaction. There should be at least additional controls, including beads+ antibody without lysate, additional control antigens that do not co-IP. For each IP the provided data have a problem. The co-IP with anti-APP antibodies shows a moderate enrichment for APP (while one would expect a dramatic higher amount in the IP-ed fraction compared to the input). On the contrary, the CD2AP seems to dramatically co-enrich: the levels in the input are barely detectable in contrast to the IP lane. In almost all cases one observes the reverse (high levels in input, low levels in the co-IP lane). With respect to the BACE1-Bin1 interaction: also here the BACE1 (co-ip antigen) levels in the IP lane are higher than in the input lane. Moreover, the IP lane contains 3 bands: impossible that all these bands are Bace1... If these co-IP blots are true, they can only be explained by a very strong interaction (in both cases), which is surprising as the IP is done even in more stringent conditions (TritonX100 extraction). And if these proteins interact so strongly, there should be a more evident colocalization at the immunofluorescence level: by stating that they see an increased 'overlap' the authors admit there is not much true colocalization. In fact, no single APP hot spot coincides with CD2AP immunoreactivity in dendrites ( figure 3H ). the same holds true for CD2AP-Rab5: they do not colocalize, but some organelles tend to overlap and it is the overlap the authors are measuring (for BIN1 vs BACE1, there is a better correlate). Nevertheless they use these readouts to further support interaction and localization in EE.
Minor comments:
-Most quantifications of imaging data are presented with individual data points combined with mean values and SEM. In these sets, the representative images correlate with the quantifications. In few cases, however, the authors use a line diagram (e.g. 2E, EV3C): in both cases, the representative images do not follow the quantification (although, if I read correctly, quantifications are similar and normalized). Based on the images, I would expect that the 'red line' (siCD2AP in 2E and Leupeptin in EV3C) would go higher than 100%, but it remains a straight horizontal line. Can the authors clarify this? Also related to the EV3C: the authors show that upon leupeptin treatment 22C11 accumulates and is not degraded. However, and this was the point of the critique, they do not show whether this represents full length APP or the shedded ectodomain that is accumulating.
-Related to the specificity of Bin1 recruiting BACE1 into recycling tubules: given that there are no conclusive data on the Bin1-Bace1 interaction, it should be of added value to show that besides Bace1 also TFR is recycled in a Bin1-dependent manner: in fact, repeat experiment 6E with internalized Tfr-488.
The authors have addressed all the concerns raised by this referee, who now recommends publication in EMBO Reports.
The authors fulfilled our requests. Regarding the comment (2), I would suggest the reviewers to refer a paper by Buggia-Prévot, V. et al., Mol. Neurodegener. 9, 1 (2014) to support the assumption that the trafficking of exogenous C-terminally tagged BACE1 is similar to that of endogenous BACE1.
Cross-comments from referee 3: Regarding these specificity issues, I agree with both concerns raised by the reviewer. However, the accumulation of intracellular Aβ was not a major focus in this manuscript. If they are able to show the increase in the intracellular Aβ by different method (e.g., western blot or ELISA) and omit fig. 1 , that should be enough. Rather, this manuscript suffers the specificity of antibodies used in IP experiment, as the reviewer 1 indicated. I would suggest the authors to check the specificity of anti-APP, CD2AP and BACE1 antibodies using lysates obtained from RNAi-treated cells.
2nd Revision -authors' response 14 October 2016
The authors have submitted a revised manuscript where they have addressed the critiques of the reviewers. Major concerns were related to the specificity of the antibodies used to detect Abeta42 by imaging, the co-IP data, additional controls to distinguish lysosomal degradation and the confrontation with Miyagawa et al (2016) . The new version is indeed improved and the authors have satisfactorily many of the raised issues by including new controls and performing some additional experiments. There are however some remaining issues related to my major critiques that needs some more scrutiny. 4-With respect to the co-IP data, the authors maintain them in the manuscript with only a minor change on interpretation (from 'interaction' to 'suggestive for interaction'). Again, the authors make the wrong argumentation that this might boost interest in the search for interaction domains. My point was that if co-IP data are not scrutinized with the proper controls, they are not reliable: it doesn't make any sense to use them to steer the community into further interaction studies. The only control in these experiments is the inclusion of control IgG. That is not sufficient to claim (suggestive) interaction. There should be at least additional controls, including beads+ antibody without lysate, additional control antigens that do not co-IP. For each IP the provided data have a problem. The co-IP with anti-APP antibodies shows a moderate enrichment for APP (while one would expect a dramatic higher amount in the IP-ed fraction compared to the input). On the contrary, the CD2AP seems to dramatically co-enrich: the levels in the input are barely detectable in contrast to the IP lane. In almost all cases one observes the reverse (high levels in input, low levels in the co-IP lane). With respect to the BACE1-Bin1 interaction: also here the BACE1 (co-ip antigen) levels in the IP lane are higher than in the input lane. Moreover, the IP lane contains 3 bands: impossible that all these bands are Bace1... If these co-IP blots are true, they can only be explained by a very strong interaction (in both cases), which is surprising as the IP is done even in more stringent conditions (TritonX100 extraction). And if these proteins interact so strongly, there should be a more evident colocalization at the immunofluorescence level: by stating that they see an increased 'overlap' the authors admit there is not much true colocalization. In fact, no single APP hot spot coincides with CD2AP immunoreactivity in dendrites ( figure 3H ). the same holds true for CD2AP-Rab5: they do not colocalize, but some organelles tend to overlap and it is the overlap the authors are measuring (for BIN1 vs BACE1, there is a better correlate). Nevertheless they use these readouts to further support interaction and localization in EE.
Response: With respect to the co-ip data we now understand the reviewer concerns and agree to remove it from the paper as it was suggested by reviewer 1 point 2 in the first revision.
-Most quantifications of imaging data are presented with individual data points combined with mean values and SEM. In these sets, the representative images correlate with the quantifications. In few cases, however, the authors use a line diagram (e.g. 2E, EV3C): in both cases, the representative images do not follow the quantification (although, if I read correctly, quantifications are similar and normalized). Based on the images, I would expect that the 'red line' (siCD2AP in 2E and Leupeptin in EV3C) would go higher than 100%, but it remains a straight horizontal line. 
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified
Please fill out these boxes ê (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
C-Reagents

B-Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
the exact sample size (n) for each experimental group/condition, given as a number, not a range; a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.
a statement of how many times the experiment shown was independently replicated in the laboratory.
Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
Please ensure that the answers to the following questions are reported in the manuscript itself. We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
